Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.
Axonal injury and neuronal loss are now recognised to be hallmarks of multiple sclerosis (MS) in addition to neuroinflammation and demyelination. This review discusses the factors that contribute to neural degeneration, and it emphasizes the need to confer neuroprotection in MS. The beneficial role of neuroinflammation is highlighted, and the possibility that glatiramer acetate enables neuroprotection in MS through beneficial inflammation is evaluated. Finally, the prospect of an experimental treatment, minocycline, in producing neuroprotection in MS is suggested.